Rosenbaum J S, Ginsburg R, Billingham M E, Hoffman B B
J Pharmacol Exp Ther. 1987 Apr;241(1):354-60.
New England Deaconness Hospital rats harboring a transplantable pheochromocytoma exhibit plasma norepinephrine concentrations 20-fold higher than controls. A cardiomyopathy (CM) characterized by multifocal areas of interstitial and replacement fibrosis, mixed inflammatory infiltrates and contraction band necrosis is evident 35 to 45 days after tumor implantation. Using a morphological scoring system of 0 (no cardiac damage) to 3 (involvement of almost the complete ventricular cross-section sampled), a CM score of 1.8 +/- 0.1 was found in rats harboring pheochromocytoma, a significant increase over that in age- and sex-matched controls (0.4 +/- 0.1, P less than .001). The pheochromocytoma rats also had hypertension (systolic blood pressure = 182 +/- 4 vs. 131 +/- 2 mm Hg in controls, P less than .001). In an effort to prevent the CM, rats harboring pheochromocytoma were treated with either the beta receptor antagonist timolol, the alpha receptor antagonists phentolamine or phenoxybenzamine or the nonspecific vasodilator hydralazine. Hydralazine normalized systolic blood pressure (135 +/- 6 mm Hg), whereas timolol (144 +/- 5 mm Hg), phenoxybenzamine (166 +/- 5 mm Hg) or phentolamine (154 +/- 10 mm Hg) only moderately decreased blood pressure in rats harboring pheochromocytoma. Hydralazine had no effect on CM score (1.8 +/- 0.1). Timolol markedly attenuated the CM score (0.6 +/- 0.1), whereas the alpha adrenergic antagonists were not as effective (phenoxybenzamine CM score = 1.3 +/- 0.2; phentolamine CM score = 1.7 +/- 0.2). Furthermore, timolol prevented desensitization of beta adrenergic receptor-mediated contraction in the hearts of rats harboring pheochromocytoma.(ABSTRACT TRUNCATED AT 250 WORDS)
新英格兰女执事医院中患有可移植嗜铬细胞瘤的大鼠,其血浆去甲肾上腺素浓度比对照组高20倍。肿瘤植入后35至45天,出现一种以多灶性间质和替代性纤维化、混合性炎性浸润及收缩带坏死为特征的心肌病(CM)。使用从0(无心脏损伤)到3(几乎累及所取心室完整横截面)的形态学评分系统,发现患有嗜铬细胞瘤的大鼠CM评分为1.8±0.1,与年龄和性别匹配的对照组(0.4±0.1,P<0.001)相比显著增加。嗜铬细胞瘤大鼠也患有高血压(收缩压=182±4 vs.对照组131±2 mmHg,P<0.001)。为了预防CM,对患有嗜铬细胞瘤的大鼠用β受体拮抗剂噻吗洛尔、α受体拮抗剂酚妥拉明或酚苄明或非特异性血管扩张剂肼屈嗪进行治疗。肼屈嗪使收缩压恢复正常(135±6 mmHg),而噻吗洛尔(144±5 mmHg)、酚苄明(166±5 mmHg)或酚妥拉明(154±10 mmHg)仅使患有嗜铬细胞瘤的大鼠血压适度降低。肼屈嗪对CM评分无影响(1.8±0.1)。噻吗洛尔显著降低CM评分(0.6±0.1),而α肾上腺素能拮抗剂效果较差(酚苄明CM评分为1.3±0.2;酚妥拉明CM评分为1.7±0.2)。此外,噻吗洛尔可防止患有嗜铬细胞瘤大鼠心脏中β肾上腺素能受体介导的收缩脱敏。(摘要截断于250字)